Literature DB >> 10889175

Refractory celiac disease.

B M Ryan1, D Kelleher.   

Abstract

Celiac disease is a gluten-sensitive enteropathy, characterized by villous atrophy, which is reversed by gluten withdrawal. A minority of patients with celiac-like enteropathy are resistant to gluten-free diet, so-called refractory sprue, or unclassified sprue. Refractory sprue is a diagnosis of exclusion; all other causes of a celiac-like enteropathy must be eliminated before a diagnosis of refractory sprue can be made. Recent evidence suggests that refractory sprue comprises a heterogenous group of patients with diverse underlying causes. A small proportion of these patients seem to have an adult form of autoimmune enteropathy, characterized by the presence of antienterocyte antibodies. However, a larger group of patients with refractory sprue now seem to have a cryptic intestinal T-cell lymphoma, characterized by the presence of phenotypically abnormal, monoclonal intraepithelial lymphocytes, despite benign cytology. Current therapeutic options include nutritional support and immunosuppressive therapy, but response is variable. The prognosis of refractory sprue may be poor; patients may die of severe malabsorption, or through synchronous or metachronous development of an enteropathy-associated T-cell lymphoma. Based on this recent evidence, patients with refractory sprue should be screened for antienterocyte antibodies and have T-cell receptor and monoclonal antibody studies performed; this could facilitate identification of cases of adult-onset autoimmune enteropathy and those of cryptic T-cell lymphoma. Moreover, early recognition of the malignant nature of the intestinal infiltrate in some cases of refractory sprue could permit the development of novel chemotherapeutic regimens for this condition.

Entities:  

Mesh:

Year:  2000        PMID: 10889175     DOI: 10.1053/gast.2000.8530

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  25 in total

1.  Gastrointestinal intraepithelial lymphocytes and T cell lymphomas.

Authors:  I N Farstad; K E A Lundin
Journal:  Gut       Date:  2003-02       Impact factor: 23.059

Review 2.  Refractory sprue.

Authors:  Andrea N Culliford; Peter H R Green
Journal:  Curr Gastroenterol Rep       Date:  2003-10

3.  A review of rifaximin and bacterial overgrowth in poorly responsive celiac disease.

Authors:  Matthew S Chang; Peter H R Green
Journal:  Therap Adv Gastroenterol       Date:  2012-01       Impact factor: 4.409

Review 4.  Classification and management of refractory coeliac disease.

Authors:  Alberto Rubio-Tapia; Joseph A Murray
Journal:  Gut       Date:  2010-04       Impact factor: 23.059

Review 5.  An approach to duodenal biopsies.

Authors:  S Serra; P A Jani
Journal:  J Clin Pathol       Date:  2006-05-05       Impact factor: 3.411

Review 6.  Refractory celiac disease.

Authors:  Hani Abdallah; Daniel Leffler; Melinda Dennis; Ciarán P Kelly
Journal:  Curr Gastroenterol Rep       Date:  2007-10

7.  Adult coeliac disease in Ireland: a case series.

Authors:  A Saleem; H J O' Connor; P O' Regan
Journal:  Ir J Med Sci       Date:  2011-12-28       Impact factor: 1.568

8.  Heterogeneity of intraepithelial lymphocytes in refractory sprue: potential implications of CD30 expression.

Authors:  I N Farstad; F-E Johansen; L Vlatkovic; J Jahnsen; H Scott; O Fausa; A Bjørneklett; P Brandtzaeg; T S Halstensen
Journal:  Gut       Date:  2002-09       Impact factor: 23.059

9.  Clinical staging and survival in refractory celiac disease: a single center experience.

Authors:  Alberto Rubio-Tapia; Darlene G Kelly; Brian D Lahr; Ahmet Dogan; Tsung-Teh Wu; Joseph A Murray
Journal:  Gastroenterology       Date:  2008-10-08       Impact factor: 22.682

10.  Visualization of transepithelial passage of the immunogenic 33-residue peptide from alpha-2 gliadin in gluten-sensitive macaques.

Authors:  Kaushiki Mazumdar; Xavier Alvarez; Juan T Borda; Jason Dufour; Edith Martin; Michael T Bethune; Chaitan Khosla; Karol Sestak
Journal:  PLoS One       Date:  2010-04-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.